, on Friday finished a £7.48 million private placing to further the clinical development of Clevegen®.
Dr Markku Jalkanen, CEO of Faron, commented: "This financing will allow us to further progress our clinical programme on Clevegen with a view to clarifying its full potential, either alone or in combination with existing cancer treatments.”
Faron’s MATINS trial showed that Clevegen® promoted immune activation in patients, potentially making it a new and effective macrophage immune checkpoint drug for cancer patients.
Dr. Jalkanen said: “This is very important as many, if not all, cancer patients have reduced immune capacity to defend them against cancer spread and may potentially be focal information in terms of specifying our goals for the ongoing partnering discussions."
Shares in Faron were trading 10.47% higher at 237.5p after the fundraise
Shares in Faron have risen by about 350% year to date.
3,935,500 shares were placed at 190p, representing about 10% of Faron’s issued share capital before the placing.
Faron told investors that the proceeds are expected to provide twelve months of working capital.
The company is to advance Clevegen, initiating the cohort expansion of the MATINS trial in colorectal cancer, eventually sharing the data with the US FDA to discuss a biologics licence application.
It is also having a face-to-face meeting with the FDA in early December to discuss Traumakine, its phase III treatment for acute respiratory distress.
Faron also welcomed the significant number of new Nordic shareholders after the placing, after Swedish firm Carnegie Investment Bank AB acted as financial adviser and bookrunner.
Follow News & Updates from Faron Pharmaceuticals here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
The AIM-listed processing company also said it had received expressions of interest from potential customers for almost double its annual capacity of 20,000 tonnes of antimony metal and trioxide.
“The potential scale and opportunity of this development is truly significant, especially given the potential synergies with our ongoing development of coal mine and mine mouth power,” commented Naheed Memon, Chief Executive of Oracle.
Kape CEO Ido Erlichman said: “In one acquisition, I believe we have positioned Kape to fast become one of the leading digital privacy service providers in the world, empowering consumers to manage their own data and digital security.”
SP Angel research note on commodities and miners, featuring: Adriatic Metals* (ADT AU) A$1.31, Mkt cap A$226.1m – Vares scoping study Arc Minerals* (ARCM LN) 2.7p, Mkt Cap £20m – Arc agrees sale of Šturec as it focuses resources on development of Cheyeza East discovery in Zambia Cora Gold* (CORA LN) 5.4p, Mkt Cap £7m – 5,000m of drilling to test lateral and dip extensions at Sanankoro Oriole Resources (ORR LN) 0.39p, Mkt cap £2.7m – Financing for Thani Stratex Resources Djibouti Pensana Metals (PM8 AU) A$0.20, Mkt cap A$30m – Pensana punchy on NdPr prices in new Feasibility Study Tri-Star Resources* (TSTR LN) 37p, Mkt Cap £35.2m – First production of commercial grade antimony metal
Matt Lofgran, Chief Executive Officer of Nostra Terra explained the company decision, commenting, “We have taken the view that because the asset is loss-making and given we are not the operator, despite the fact that we feel that we could improve operations significantly, ultimately the best resolution is for NTI to transfer its interest and have no past or future liability."
“Transport refuelling is just the tip of the iceberg for demand for hydrogen from renewable sources,” said Dr Graham Cooley, CEO of ITM Power, “and this partnership will be well positioned to participate in this exciting and rapidly growing industry."